A previous study reports that administering Her2/neu DNA vaccination to HSP90B1 HER2+ breast cancer-carrying mice improved immune response against tumours, which was indicated by higher IFN-/IL-4 levels and reduced Tregs at the tumour site [19]. This evidence concerns the gene ERBB2 and breast cancer.